One blood draw, two different answers about neurodegeneration
New blood biomarkers for ALS and Parkinson's split two questions doctors used to conflate: how fast the disease is moving, and how far along it is. The split could change how trials pick patients and track whether a drug works.
- Circulating gelsolin tracks disease stage in ALS across four independent cohorts, in a preprint. Self-reported m:…3940
- Gelsolin explains 19% of the variance in ALS disease stage measured by functional decline, in a preprint. Self-reported m:…3940
- 72 plasma proteins track the rate of functional decline in ALS, while baseline neurofilament light chain predicts speed but does not track change, in a preprint. Self-reported m:…6071
- In early Parkinson's, higher baseline levels of P-tau217 and NfL are associated with greater hazards of worse cognitive and balance outcomes, in a preprint. Self-reported m:…6072
Two numbers instead of one
Neurodegeneration has long had a measurement problem: a patient can be declining fast from an early stage, or slowly from a late one, and a single number cannot tell those apart. Three preprints posted this week suggest blood tests are finally splitting the two questions. One set of markers tracks how far along the disease is. Another tracks how fast it is moving. The distinction matters because a drug trial needs both: stage to pick comparable patients, and speed to tell whether the drug slowed anything down. m:…3940 m:…6071
The clearest statement of the split comes from ALS, where neurofilament light chain, known as NfL, has been the standard marker. The new work finds that NfL tracks disease aggressiveness but not disease stage. In other words, NfL says something about how fast the disease is going, but not about how much of the journey from onset to death has already passed. That gap is what the new markers aim to fill. m:…3940
ALS: a stage marker and a speed marker
The stage marker is circulating gelsolin, or GSN. A preprint reports that GSN tracks disease stage in ALS across four independent cohorts, and that it explains 19% of the variance in disease stage quantified by functional decline. Nineteen percent is not a complete answer, and the authors do not present it as one, but it is a real signal for a quantity that previously had no blood-based measure at all. A stage marker lets a trial compare patients who are at the same point in the disease, rather than mixing early and late patients and hoping the difference averages out. m:…3940
The speed marker comes from a second ALS preprint, which identified 72 plasma proteins that track the rate of functional decline. The key contrast in that paper is with NfL: baseline NfL predicts the speed of decline but does not track longitudinal changes, whereas the identified progression markers do. The markers also track decline within every stratum of baseline NfL, which means they add information on top of the standard test rather than repeating it. And motor neuron proteins are underrepresented among the progression markers, which suggests the signal is systemic rather than a direct readout of dying motor neurons. m:…6071
Parkinson's: a forecast, not a diagnosis
The Parkinson's paper makes a subtler point. Researchers evaluated plasma P-tau217, NfL and GFAP in early sporadic Parkinson's disease and found that baseline levels of these markers do not differ between early Parkinson's patients and healthy controls. As a diagnostic test at the earliest stage, in other words, they do not separate the two groups. But higher baseline levels of P-tau217 and NfL in early Parkinson's are associated with greater hazards of worse cognitive and balance outcomes, and the levels are associated with longitudinal change in cognitive scores. m:…6072
The implication is that these markers are prognostic rather than diagnostic in early disease: they say less about whether someone has Parkinson's, and more about what course the disease is likely to take. For a clinician, that is a different kind of information, and arguably a more useful one once the diagnosis is already made. For a trial, it is a way to enrich for patients likely to decline on the outcomes being measured, which is how smaller trials can still detect a drug effect. m:…6072
What would have to be true next
All three papers are preprints, and none of them claims these markers are ready for routine clinical use. The ALS findings rest on cohort studies, and the Parkinson's findings on association with future outcomes, not on a demonstration that acting on the markers improves care. The honest reading is that the measurement toolkit for neurodegeneration is getting finer, and the split between speed and stage is now measurable in blood. What remains is the harder work: showing that trials using these markers run better, and that patients whose care is guided by them do better. m:…3940 m:…6071 m:…6072
For drug developers, the near-term use is the clearest: better stratification and better monitoring in trials. For clinicians, the near-term use is prognostic conversation with patients who want to know what to expect. Both uses depend on the same thing, which is replication in larger and more diverse cohorts, and a clear statement of what each marker can and cannot say. m:…3940 m:…6072
What is still unresolved
- Whether gelsolin's stage signal replicates outside the four studied cohorts.
- Whether the 72-protein ALS progression panel works in the fastest-progressing patients.
- Whether Parkinson's plasma markers predict outcomes in cohorts beyond the one studied.
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.